A PHASE IB EXPANSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS CUDC-101 IN SUBJECTS WITH ADVANCED HEAD AND NECK, GASTRIC, BREAST, LIVER AND NON-SMALL CELL LUNG CANCER TUMORS: